Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.45 HKD | -2.07% | -10.03% | -27.80% |
01:38pm | Keymed's Anti-Rhinosinusitis Drug Set For Priority Review in China | MT |
Apr. 30 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.80% | 1.28B | |
+10.89% | 115B | |
+12.48% | 106B | |
-4.30% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-12.92% | 17.56B | |
-40.50% | 17.32B | |
+6.44% | 14.03B | |
+31.21% | 12.13B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed Presents Phase 1 Trial Data for Gastric/Gastroesophageal Cancer Drug